Dynavax Technologies Corporation
Dynavax Technologies — Q2 2025 Earnings Presentation
19 slides from Dynavax Technologies's earnings presentation, Aug 7, 2025
Slide 1: Earnings Report Q2'25
Earnings Report Q2’25 Using Proven, Innovative Adjuvant Technology to Help Protect the World Against Infectious Diseases August 2025 Nasdaq: DVAX
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Dynavax's expected financial results and market
Slide 3: Executing on Our Strategy: Q2'25 Highlights
CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Executing on Our Strategy: Q2’25 Highlights Achieve HEPLISAV-B® Advancing Clinical Delivering Strong Quarterly Sales Record Pipeline Milestones Financial Profile Net product revenue: Shingles vaccine program: Cash, cash
Slide 4: Our Core Strategic Priorities
CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE OUR CORE STRATEGIC PRIORITIES Maximizing HEPLISAV-B’s Advancing Diversified Vaccine Continue Balanced Allocation of Commercial Potential Pipeline With CpG 1018® Adjuvant Capital to Accelerate Growth • Achieve at least 6
Slide 5: CpG 1018: Leveraging Our Proven Adjuvant Across Pipeline
CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE CpG 1018: Leveraging Our Proven Adjuvant Across Pipeline Well-defined Mechanism of Action (MOA) & Clinical Profile Proprietary CpG 1018 1 adjuvant selectively activates TLR9, an important 2 toll-like receptor that elici
Slide 6: HEPLISAV-B Clinical Outcomes
CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE HEPLISAV-B® Primary Endpoint Results: Study 2 per protocol population (ages 40-70)1, N=1,482 [Hepatitis B Vaccine (Recombinant), Adjuvanted] HEPLISAV-B Engerix-B Clinical Outcomes Primary endpoint Primary endpoint 100%
Slide 7: Continued HEPLISAV-B Growth: Revenue & Market Share
CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Continued HEPLISAV-B Growth: Revenue & Market Share HEPLISAV-B Total U.S. Market Share1 HEPLISAV-B Vaccine Annual Net Product Revenue ($M)2 Quarter End Trailing-12-Month (TTM) 50% ~17-21% 325 Anticipated 65% CAGR 2025 N
Slide 8: HEPLISAV-B Market Opportunity Expected to Surpass $900M in U.S. by 2030
CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE HEPLISAV-B Market Opportunity Expected to Surpass $900M in U.S. by 2030 Source: Internal data and company estimates. Not independently verified. 1Based on 2024 U.S. adult Hepatitis B vaccines net sales, adjusted for com
Slide 9: U.S. Hep B Vaccine Sales Expected to Surpass $900M by 2030
CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE U.S. Hep B Vaccine Sales Expected to Surpass $900M by 2030 HEPLISAV-B is the market share leader in the largest projected growth segment (Retail Pharmacy) 2024 Market Size: ~$615M1 2030 Projected Market Size: >$900M2 Di
Slide 10: Vaccine Development Pipeline
CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Vaccine Development Pipeline IND- BLA Program enabling Phase 1 Phase 2 Phase 3 Review Partner Planned Milestones • Report top-line Part 1 Phase 1/2 trial results in August 2025 (1-month Wholly follow up data) Shingles V
Slide 11: Shingles Vaccine Program: New Options Needed
CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Shingles Vaccine Program: New Options Needed Current Market-Leading Vaccine Associated with Adverse Events1 Herpes Zoster (shingles) is an extremely Program Status: painful consequence of the reactivation of a • Complet
Slide 12: Shingles Vaccine Program: Path to Establishing Proof-of-Concept
CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Shingles Vaccine Program: Path to Establishing Proof-of-Concept for a Differentiated and Best-in-Class Shingles Vaccine Key Trial Objectives / Next Steps PHASE 1 PHASE 1/2 FUTURE DEVELOPMENT CLINICAL TRIAL CLINICAL TRIA
Slide 13: Z-1018 Demonstrated Improved Tolerability and Similar Immunogenicity Compared to Shingrix in Phase 1
CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Shingles Vaccine Program Z-1018 Demonstrated Improved Tolerability and Similar Immunogenicity Compared to Shingrix in Phase 1 Tolerability Immunogenicity Rate of moderate/severe Vaccine Response Rate (VRR)2 Post Injecti
Slide 14: Additional Pipeline Programs
CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Additional Pipeline Programs Plague Vaccine Pandemic Influenza Adjuvant Lyme Disease Vaccine Government agencies research and One of the most persistent and Bacterial infection that is the most stockpile medical counter
Slide 15: Financial Summary
CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Financial Summary Q2’25 Financial Highlights Full Year 2025 Financial Guidance2 Financial Summary ($M) Q2’25 Q2’24 % Change HEPLISAV-B Net Revenue Total Revenues 95.4 73.8 29% HEPLISAV-B Net Product Revenue 91.9 70.2 31
Slide 16: Executing on Our Strategy: Q2'25 Highlights
CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Executing on Our Strategy: Q2’25 Highlights Achieve HEPLISAV-B® Advancing Clinical Delivering Strong Quarterly Sales Record Pipeline Milestones Financial Profile Net product revenue: Shingles vaccine program: Cash, cash
Slide 17: Thank you
Thank you August 2025 Nasdaq: DVAX
Slide 18: Non-GAAP Financial Measures
Non-GAAP Financial Measures To supplement our financial results presented on a GAAP basis, we have included information about Adjusted EBITDA, a non-GAAP financial measure. We believe the presentation of this non-GAAP financial measure, when viewed with our results under GAAP and the accompanying re
Slide 19: Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA
Dynavax Technologies Corporation Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA (In Thousands) (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 GAAP net income (loss) $ 18,721 $ 11,386 $ (77,378) $ 2,665 Adjustments: Depreciation & amortization 374 3